Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
IR_propancbiopharma
IR_propancbiopharma Dec. 24 at 7:56 PM
$PPCB Propanc recently engaged with academic collaborators in Granada, Spain, as part of its ongoing research activities supporting the development of PPCB. These scientific exchanges provide an opportunity to align laboratory work with broader research objectives and review progress across multiple areas of investigation. We especially want to thank Dr. Belén Toledo, Dr. Aitor González and Professor Macarena Perán for their commitment, strong investigation, and dedicated involvement in our current research. Academic collaboration remains a core component of Propanc’s research model, enabling the Company to explore complex biological processes relevant to cancer and chronic disease while advancing its proenzyme platform within a rigorous research framework.
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 5:11 PM
$PPCB stalking the price a bit...
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 2:44 PM
$PPCB Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts https://www.rapidticker.com/news/ppcb-propanc-biopharma-publishes-impact-of-95bbb1
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 15 at 3:16 PM
$PPCB Exploring PRP’s Relevance Across Cancer and Fibrosis Scientists at the University of Jaén and University of Granada are investigating how PRP affects EMT and fibroblast activation — shared mechanisms between metastatic cancer and chronic fibrosis. These findings contribute to Propanc’s recent provisional patent applications covering resistant cancer and fibrosis methods. This research expands the therapeutic potential of the proenzyme platform into disease areas driven by long-term tissue damage. Propanc remains focused on strengthening its intellectual-property position while advancing targeted research toward future clinical milestones.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 12 at 6:26 PM
$PPCB Understanding Chemoresistance in KRAS-Mutant Tumors Academic collaborators are using pancreatic tumor organoids with KRAS mutations (G12D, G12V, G12R) and loss of p53 function to study aggressive tumor behavior and resistance to chemotherapy. Pancreatic tumor organoids These 3D models preserve cancer stem cell properties, enabling evaluation of: • Tumor heterogeneity • Metastatic potential • Responses to regimens such as FOLFIRINOX Pancreatic tumor organoids Insights from this system inform how PRP may interact with chemoresistant cancer, including target selection for future clinical development. These insights support Propanc’s evaluation of PRP in aggressive tumor settings. The work helps guide future development decisions as the Company prepares for clinical advancement.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 10 at 9:57 PM
$PPCB Advancing PRP Toward Phase 1b Clinical Evaluation Propanc is preparing its lead candidate, PRP, for a planned Phase 1b First-in-Human study in patients with advanced solid tumors. The 12-month trial is designed to assess dosing, safety, and preliminary clinical signals. Following this initial study, Propanc intends to conduct targeted Phase 2 evaluations across selected cancer types to determine where PRP’s mechanism can deliver the greatest clinical benefit. These steps reflect Propanc’s progress toward translating its enzyme-based platform into patient impact.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 9 at 11:49 PM
$PPCB Investigating Mesenchymal Drift in Cancer and Chronic Disease Propanc Biopharma is studying how PRP may influence biological changes tied to epithelial-to-mesenchymal transition (EMT), a process linked to tumor spread, fibrosis, and tissue decline. Research efforts include evaluating how proenzyme activation may modulate these pathways over time. This line of inquiry supports Propanc’s long-term scientific strategy. It also reflects the potential to extend the Company’s proenzyme technology beyond oncology into interconnected chronic diseases. The team continues advancing this investigative work as part of Propanc’s broader commitment to translating emerging biology into clinical innovation.
0 · Reply
MacAwoo
MacAwoo Dec. 9 at 3:31 PM
$PPCB jeez 😅
0 · Reply
newbulloh2
newbulloh2 Dec. 5 at 12:07 AM
$PPCB reallly wished yalll could have pamped this lityle higher oh well gains a gain!!!
1 · Reply
JeanBets
JeanBets Dec. 4 at 3:24 PM
$PPCB 🦍⭐️💰
0 · Reply
Latest News on PPCB
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 2 days ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 20 days ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 23 days ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 5 weeks ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 6 weeks ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 7 weeks ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 2 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 2 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 2 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 3 months ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 4 months ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Provides Shareholder Update

Aug 25, 2025, 7:30 AM EDT - 4 months ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 4 months ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

Aug 16, 2025, 12:25 AM EDT - 4 months ago

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

BLSH BUUU KLAR MAGH MIAX NSRX NUTR

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 4 months ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

IR_propancbiopharma
IR_propancbiopharma Dec. 24 at 7:56 PM
$PPCB Propanc recently engaged with academic collaborators in Granada, Spain, as part of its ongoing research activities supporting the development of PPCB. These scientific exchanges provide an opportunity to align laboratory work with broader research objectives and review progress across multiple areas of investigation. We especially want to thank Dr. Belén Toledo, Dr. Aitor González and Professor Macarena Perán for their commitment, strong investigation, and dedicated involvement in our current research. Academic collaboration remains a core component of Propanc’s research model, enabling the Company to explore complex biological processes relevant to cancer and chronic disease while advancing its proenzyme platform within a rigorous research framework.
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 5:11 PM
$PPCB stalking the price a bit...
0 · Reply
JohnTrack
JohnTrack Dec. 22 at 2:44 PM
$PPCB Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts https://www.rapidticker.com/news/ppcb-propanc-biopharma-publishes-impact-of-95bbb1
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 15 at 3:16 PM
$PPCB Exploring PRP’s Relevance Across Cancer and Fibrosis Scientists at the University of Jaén and University of Granada are investigating how PRP affects EMT and fibroblast activation — shared mechanisms between metastatic cancer and chronic fibrosis. These findings contribute to Propanc’s recent provisional patent applications covering resistant cancer and fibrosis methods. This research expands the therapeutic potential of the proenzyme platform into disease areas driven by long-term tissue damage. Propanc remains focused on strengthening its intellectual-property position while advancing targeted research toward future clinical milestones.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 12 at 6:26 PM
$PPCB Understanding Chemoresistance in KRAS-Mutant Tumors Academic collaborators are using pancreatic tumor organoids with KRAS mutations (G12D, G12V, G12R) and loss of p53 function to study aggressive tumor behavior and resistance to chemotherapy. Pancreatic tumor organoids These 3D models preserve cancer stem cell properties, enabling evaluation of: • Tumor heterogeneity • Metastatic potential • Responses to regimens such as FOLFIRINOX Pancreatic tumor organoids Insights from this system inform how PRP may interact with chemoresistant cancer, including target selection for future clinical development. These insights support Propanc’s evaluation of PRP in aggressive tumor settings. The work helps guide future development decisions as the Company prepares for clinical advancement.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 10 at 9:57 PM
$PPCB Advancing PRP Toward Phase 1b Clinical Evaluation Propanc is preparing its lead candidate, PRP, for a planned Phase 1b First-in-Human study in patients with advanced solid tumors. The 12-month trial is designed to assess dosing, safety, and preliminary clinical signals. Following this initial study, Propanc intends to conduct targeted Phase 2 evaluations across selected cancer types to determine where PRP’s mechanism can deliver the greatest clinical benefit. These steps reflect Propanc’s progress toward translating its enzyme-based platform into patient impact.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Dec. 9 at 11:49 PM
$PPCB Investigating Mesenchymal Drift in Cancer and Chronic Disease Propanc Biopharma is studying how PRP may influence biological changes tied to epithelial-to-mesenchymal transition (EMT), a process linked to tumor spread, fibrosis, and tissue decline. Research efforts include evaluating how proenzyme activation may modulate these pathways over time. This line of inquiry supports Propanc’s long-term scientific strategy. It also reflects the potential to extend the Company’s proenzyme technology beyond oncology into interconnected chronic diseases. The team continues advancing this investigative work as part of Propanc’s broader commitment to translating emerging biology into clinical innovation.
0 · Reply
MacAwoo
MacAwoo Dec. 9 at 3:31 PM
$PPCB jeez 😅
0 · Reply
newbulloh2
newbulloh2 Dec. 5 at 12:07 AM
$PPCB reallly wished yalll could have pamped this lityle higher oh well gains a gain!!!
1 · Reply
JeanBets
JeanBets Dec. 4 at 3:24 PM
$PPCB 🦍⭐️💰
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 2:32 PM
$QCLS LFG HOLDING FOR GOLD!!! 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my $TSLA $COIN profits into EPOW👇💰💰💰 $PPCB $QCLS let’s goooooo
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 2:30 PM
$INTS watching… 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my $TSLA $COIN profits into EPOW👇💰💰💰 $PPCB $QCLS let’s goooooo
0 · Reply
TheRoaringBunny
TheRoaringBunny Dec. 4 at 2:29 PM
$COIN $GNPX $PPCB $QCLS $TSLA GNPX IS VERIFIED FRESH SQUEEZE Let’s help Tim Print (his avg is $5-6)! PT $8
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 2:22 PM
$PMCB BOOM!!! 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my $TSLA $COIN profits into EPOW👇💰💰💰 $PPCB $QCLS let’s goooooo
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 2:20 PM
$JTAI watching… 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my $TSLA $COIN profits into EPOW👇💰💰💰 $PPCB $QCLS let’s goooooo
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 2:15 PM
$GNPX watching … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my $TSLA $COIN profits into EPOW👇💰💰💰 $PPCB $QCLS let’s goooooo
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 2:07 PM
$PMCB there it goes ….. 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my $TSLA $COIN profits into EPOW👇💰💰💰 $PPCB $QCLS let’s goooooo
1 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 1:56 PM
$PLRZ there it goes … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my $TSLA $COIN profits into EPOW👇💰💰💰 $PPCB $QCLS let’s goooooo
0 · Reply
GuyFawkes_EOD
GuyFawkes_EOD Dec. 4 at 1:54 PM
$PPCB careful, they got no cash, probably a pump before offering
0 · Reply
DaBullRunner
DaBullRunner Dec. 4 at 1:51 PM
$PPCB there it goes … 🚨EPOW🚨 just received a $30M contract That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰
0 · Reply
newbulloh2
newbulloh2 Dec. 4 at 1:48 PM
$PPCB shorrt .94
0 · Reply
Stock_Catcher
Stock_Catcher Dec. 4 at 1:47 PM
$PPCB Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
0 · Reply